首页> 美国卫生研究院文献>other >Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering
【2h】

Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering

机译:胚胎心脏祖细胞和心脏组织工程的心脏再生

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Myocardial infarction (MI) is the leading cause of death worldwide. Recent advances in stem cell research hold great potential for heart tissue regeneration through stem cell-based therapy. While multiple cell types have been transplanted into MI heart in preclinical studies or clinical trials, reduction of scar tissue and restoration of cardiac function have been modest. Several challenges hamper the development and application of stem cell-based therapy for heart regeneration. Application of cardiac progenitor cells (CPCs) and cardiac tissue engineering for cell therapy has shown great promise to repair damaged heart tissue. This review presents an overview of the current applications of embryonic CPCs and the development of cardiac tissue engineering in regeneration of functional cardiac tissue and reduction of side effects for heart regeneration. We aim to highlight the benefits of the cell therapy by application of CPCs and cardiac tissue engineering during heart regeneration.
机译:心肌梗塞(MI)是全球主要的死亡原因。干细胞研究的最新进展通过基于干细胞的疗法为心脏组织再生提供了巨大潜力。尽管在临床前研究或临床试验中已将多种细胞类型移植到MI心脏中,但瘢痕组织的减少和心脏功能的恢复一直不大。若干挑战阻碍了基于干细胞的心脏再生疗法的开发和应用。心脏祖细胞(CPC)和心脏组织工程技术在细胞治疗中的应用已显示出修复受损心脏组织的巨大希望。这篇综述概述了胚胎CPC的当前应用以及心脏组织工程在功能性心脏组织再生和减少心脏再生副作用方面的发展。我们旨在通过在心脏再生过程中应用CPC和心脏组织工程来强调细胞疗法的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号